Glaxo drug cuts bleeding in study
GlaxoSmithKline's experimental platelet boosting drug eltrombopag has produced further positive results in patients with idiopathic thrombocytopenia purpura (ITP), researchers said on Saturday.
Eltrombopag, which Glaxo plans to sell as Revolade in Europe and Promacta in the United States, is one of several novel drugs in the group's pipeline which it believes have blockbuster potential.
Results from a pivotal Phase III study presented at the European Hematology Association congress in Vienna showed 50 to 75 milligrams once daily resulted in a statistically significant increase in platelet counts and also reduced bleeding in people with chronic ITP.
The placebo-controlled trial involved 114 adults and patients studied had previously received and failed current standard ITP treatments.
ITP is an autoimmune disease which results in low blood platelet counts. Because platelets contribute to blood clotting, patients with low counts bleed more easily than others, heal more slowly and bruise more often.
Eltrombopag, which is given as a pill, was discovered as a result of a research collaboration between Glaxo and Ligand Pharmaceuticals Inc.
- 1 RBS gets Chinese approval for Suzhou stake
- 2 June retail sales fall less than expected
- 3 Birth control battle weighs on Philippine economy
- 4 Saudi Telecom in sponsorship deal with Man United
- 5 Glasgow loss deals blow to Labour
- 6 Besley says fighting inflation tough task
- 7 Asia stocks at two-year low
- 1 Banks may avoid worst of household debt pain
- 2 FAA proposes 3.8 million fine against American
- 3 Swaps spreads highlight credit stresses
- 4 Slower economy saps climate action
- 5 Besley says fighting inflation tough task
- 6 Poll shows leader swap would not save Labour
- 7 Weak sterling may not curb recession
|
- 1 RBS gets Chinese approval for Suzhou stake
- 2 Buyout group raises offer for Australia's Indophil
- 3 Nat Exp and Stagecoach on rail bid shortlist
- 4 Tolent posts fall in first-half pretax profit
- 5 HP results top Wall Street targets
- 6 Apple updates iPhone software to fix glitches
- 7 BAA set for break-up
|
|
